drugset / Trial / NCT06636981
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
Non-randomizedSingle-groupOpen-labelTreatment
Summary
All trans retinoic acid Combined with Toripalimab+Chemotherapy for Locally Advanced inoperable or Metastatic Triple Negative Breast Cancer：a multi-center, multi-cohort phase II trial
Timeline
- Start
- 2024-11-04
- Primary completion
- 2029-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Elibulin | Unknown | 1.4 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tretinoin | Small molecule | 20 mg | Oral |
| Subject | Utideron | Unknown | 40 mg/m2 | Intravenous |